Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer

Abstract Pancreatic cancer is a lethal disease with poor prognosis. Gemcitabine has been the first line systemic treatment for pancreatic cancer. However, the rapid development of drug resistance has been a major hurdle in gemcitabine therapy leading to unsatisfactory patient outcomes. With the rece...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ru Chen, Lisa A Lai, Yumi Sullivan, Melissa Wong, Lei Wang, Jonah Riddell, Linda Jung, Venu G. Pillarisetty, Teresa A. Brentnall, Sheng Pan
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
R
Q
Acceso en línea:https://doaj.org/article/4330feb75977443b89a09ae113dbd509
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!